[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360142-105":59,"doc-detail-360142-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","randomised-multicentre-phase-ii-study-of-bevacizumab-and-paclitaxel-induction-followed-by-atezolizumab-and-nab-paclitaxel-in-patients-with-pd-l1-positive-metastatic-triple-negative-breast-cancer-protocol-for-the-induce-trial-jbcrg-m10","Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)","","Addition of bevacizumab and paclitaxel as induction therapy prior to standard atezolizumab and nab-paclitaxel is evaluated for patients with programmed death-ligand 1 (PD-L1)-positive metastatic triple-negative breast cancer. A multicentre, randomised, open-label phase II trial compares two induction cycles followed by atezolizumab plus nab-paclitaxel versus standard treatment. The primary endpoint is progression-free survival per RECIST v1.1, powered on 89 events, with a target sample size of 106.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/randomised-multicentre-phase-ii-study-of-bevacizumab-and-paclitaxel-induction-followed-by-atezolizumab-and-nab-paclitaxel-in-patients-with-pd-l1-positive-metastatic-triple-negative-breast-cancer-protocol-for-the-induce-trial-jbcrg-m10/360142/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/randomised-multicentre-phase-ii-study-of-bevacizumab-and-paclitaxel-induction-followed-by-atezolizumab-and-nab-paclitaxel-in-patients-with-pd-l1-positive-metastatic-triple-negative-breast-cancer-protocol-for-the-induce-trial-jbcrg-m10/360142.png","ImageObject",300,407,{"name":92,"@type":93},"Nguyễn Văn Học","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the INDUCE trial evaluate in PD-L1-positive metastatic triple-negative breast cancer?","Question",{"text":112,"@type":113},"It evaluates whether induction therapy with bevacizumab and paclitaxel followed by atezolizumab and nab-paclitaxel improves outcomes compared with standard atezolizumab and nab-paclitaxel.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the primary endpoint of the study?",{"text":117,"@type":113},"The primary outcome is progression-free survival (PFS) assessed per Response Evaluation Criteria In Solid Tumours (RECIST), version 1.1.",{"name":119,"@type":110,"acceptedAnswer":120},"How many PFS events and patients are planned?",{"text":121,"@type":113},"The study estimates 89 PFS events are required for power, with a target sample size of 106 patients to account for dropouts.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360142,1790190882,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","Open access Protocol  \n Randomised, multicentre phase II study  \nof bevacizumab and paclitaxel induction followed by atezolizumab and nabpaclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE  \ntrial (JBCRG-M10)  \nYukinori Ozaki  ,1 Shohei Koyama,2,3,4 Satoshi Morita,5 Minoru Miyashita,6 Emi Tokuda,7 Tatsunori Shimoi  ,8 Megumi Fukuoka,9 Hiroko Masuda,10  \nYuko Takano,11 Nobuhiro Shibata  ,12,13 Tetsuhiro Yoshinami,14 Akari Murakami,15 Kentaro Tamaki,16 Hiroshi Ishiguro,17 Shigehira Saji,7 Asako Miwa,18  \nJunko Matsunaga,18 Yue Zheng,18 Hiroyoshi Nishikawa,3,9,19,20  \nNorikazu Masuda  21  \nTo cite: Ozaki Y, Koyama S, Morita S, et al. Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10) . BMJ Open 2026;16:e098088 . doi:10 . 1136/ bmjopen-2024-098088  \n► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[bmjopen-2024-098088](bmjopen-2024-098088)) .  \nReceived 17 December 2024 Accepted 31 March 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Yukinori Ozaki;  \n[yukinori.ozaki@jfcr.or.jp](yukinori.ozaki@jfcr.or.jp)  \nABSTRACT  \nIntroduction Addition of bevacizumab and paclitaxel as induction therapy prior to standard atezolizumab and nabpaclitaxel in patients with programmed death-ligand 1 (PD-L1) -positive metastatic triple-negative breast cancer (mTNBC) may help to overcome vascular endothelial growth factor-associated resistance mechanisms that limit the immune-mediated antitumour efficacy of atezolizumab and nab-paclitaxel. Methods and analysis The Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+TNBC (INDUCE) study is a multicentre, randomised, open-label, phase II trial designed to evaluate the efficacy and safety of two cycles of induction therapy with bevacizumab and paclitaxel followed by atezolizumab and nab-paclitaxel compared with standard atezolizumab and nab-paclitaxel inpatients with PD-L1-positive mTNBC. The primary outcome of the study is progression-free survival (PFS) per Response Evaluation Criteria In Solid Tumours, V.1.1. We have estimated that 89 PFS events are needed to allow a power of 80% to detect a difference between treatment groups at a one-sided significance level of 10% in this study. The target sample size is set to 106 patients to account for dropouts.  \nEthics and dissemination The study protocol and informed consent form have been approved by the Certified Research Review Board at the Nagoya University Graduate School of Medicine, Nagoya, Japan. Study results will be presented at international conferences and published in a peer-reviewed journal.  \nTrial registration number jRCTs041240039 NCT06793553 .  \nINTRODUCTION  \nThe prognosis of patients with metastatic triple-negative breast cancer (mTNBC) is  \nSTRENGTHS AND LIMITATIONS OF THIS STUDY   \n⇒ This phase II clinical trial is using robust methodology and will include a large number of centres and patients to investigate the efficacy of bevacizumab induction therapy administered prior to immune checkpoint inhibitor treatment in patients with metastatic programmed death-ligand 1-positive triplenegative breast cancer.  \n⇒ The primary endpoint of progression-free survival (PFS) is complemented by key secondary outcomes, such as 2-year PFS rate in the overall population and among patients in the induction group without disease progression at first imaging assessment, to provide a comprehensive analysis of treatment efficacy.  \n⇒ This stu","cbCaiuaiQOo0kaAW","https://ap.wps.com/l/cbCaiuaiQOo0kaAW","pdf",1730697,"English","# Abstract\n## Introduction\n## Methods and analysis\n## Ethics and dissemination\n# Strengths and limitations of this study","[{\"question\":\"What does the INDUCE trial evaluate in PD-L1-positive metastatic triple-negative breast cancer?\",\"answer\":\"It evaluates whether induction therapy with bevacizumab and paclitaxel followed by atezolizumab and nab-paclitaxel improves outcomes compared with standard atezolizumab and nab-paclitaxel.\"},{\"question\":\"What is the primary endpoint of the study?\",\"answer\":\"The primary outcome is progression-free survival (PFS) assessed per Response Evaluation Criteria In Solid Tumours (RECIST), version 1.1.\"},{\"question\":\"How many PFS events and patients are planned?\",\"answer\":\"The study estimates 89 PFS events are required for power, with a target sample size of 106 patients to account for dropouts.\"}]","Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10) | PDF",1790138868,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ddf40f7d9f43670b88aad2ae1c43dafe.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/971d2e562bebeca8734ba04481e46c60.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/416c6f1c8505c8ca65e2cc60a98e0d03.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da0224d17e3f1f6808294f93893ad5e1.webp",980,1306]